The strong efficacy and safety data could drive near-term stock appreciation. Monitor for updates on the U.S. IMPACT trial enrollment and any regulatory interactions. Given the company's small market cap and early-stage pipeline, this is a high-risk/high-reward catalyst.
Price Chart
Executive Summary
Alpha Tau announced positive clinical trial results for its Alpha DaRT therapy in pancreatic cancer, achieving 100% local disease control in 19 evaluable patients with a favorable safety profile. These results were presented at DDW 2026 and support the ongoing U.S. multicenter IMPACT trial, representing a significant milestone for the pre-commercialization biotech.
Key Facts
- 100% local disease control rate in evaluable patients from pooled analysis of two first-in-human trials of Alpha DaRT in pancreatic adenocarcinoma
- 15 of 19 evaluable patients (79%) achieved stable disease and 4 (21%) had partial response per modified RECIST v1.1
- Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
- Results presented at Digestive Disease Week (DDW) 2026, first oral presentation at a major gastroenterology conference
- Data supports ongoing U.S. multicenter pancreatic cancer IMPACT trial
Financial Impact
No financial figures provided; clinical milestone for pre-revenue company with $117M market cap
Risk Factors
- Early-stage clinical data with small sample size (n=19 evaluable) may not predict larger trial outcomes
- Alpha DaRT is not yet approved for commercial use in the U.S. or elsewhere
- Company has limited operating history and has incurred significant losses; may require additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051176 |
| Document: ea0288785-6k_alphatau.htm | 0001213900-26-051176 |
| Document: 0001213900-26-051176-index-headers.html | 0001213900-26-051176 |
| Document: 0001213900-26-051176-index.html | 0001213900-26-051176 |
| Document: 0001213900-26-051176.txt | 0001213900-26-051176 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access